trending Market Intelligence /marketintelligence/en/news-insights/trending/a_jrjnh40mo1B8qFs7C7Eg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Korea Exchange office raided in Samsung Biologics IPO probe

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Report: Korea Exchange office raided in Samsung Biologics IPO probe

Prosecutors raided the Korea Exchange's Seoul office as part of an investigation on Samsung Biologics Co. Ltd.'s 2016 IPO, Nikkei Asian Review reported.

According to the report, the stock market operator is being investigated for allegedly easing regulations to allow the Samsung C&T Corp. unit to list on the South Korean exchange. Documents and computer hard drives were collected by the authorities, in their search for information on the possible special treatment given to Samsung Biologics' 2016 listing, Nikkei added.

Samsung Biologics shares fell 4.21% to 341,000 South Korean won at market close March 15, following news of the raid.

In May 2018, South Korea's Securities and Futures Commission sent the company preliminary notification which alleged Samsung Biologics breached the country's accounting rules by inflating its net profit ahead of listing in 2016. The investigation, which concluded in July 2018, found Samsung Biologics guilty of intentionally omitting information in a public disclosure regarding Samsung Bioepis Co. Ltd., its joint venture with Cambridge, Mass.-based Biogen Inc., ahead of its listing in 2016.

The South Korean financial regulator, in a final ruling issued November 2018, imposed a fine of 8 billion won on Samsung Biologics and transferred the case to prosecutors.

Incheon, South Korea-based Samsung Biologics develops immunosuppressant biosimilars for medicines such as Enbrel, Remicade and Humira.

As of March 14, US$1 was equivalent to 1,136.48 South Korean won.